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Background: Previous research indicates a high prevalence of untreated anxiety and depres-
sion in patients with chronic obstructive pulmonary disease (COPD). The current study exam-
ined the effect of cognitive behavioral therapy (CBT) in groups for co-morbid, clinically
significant anxiety and depression in COPD outpatients of both sexes.
Methods: In a randomized, controlled trial, CBT (n Z 25) was compared with enhanced stan-
dard care (n Z 26). Participants in both conditions were followed up at 2 and 8 months from
baseline. Main outcome measures comprised the Beck Anxiety Inventory and the Beck Depres-
sion Inventory-II. Measures of health status and sleep were included as secondary outcomes.
The effects of sex and age were also investigated.
Results: CBT resulted in improvement in symptoms of anxiety and depression, with effect sizes
of 1.1 and 0.9 at post-treatment, respectively. The improvement was maintained at the
8-month follow-up, with effect sizes of 1.4 and 0.9. In the control group, there was no signif-
icant change. Compared to men, women had higher symptom levels throughout the whole
study period. Younger patients had more anxiety and depression, age had also differential
effects in the two groups on change in depressive symptoms. Changes in sleep and health
status were small in both groups.
Conclusions: The findings indicate that CBT may provide rapid symptom relief for COPD
patients with clinically significant anxiety and depression, and underline the need for inte-
grating mental health care into the overall medical regimen for COPD.
ª 2010 Elsevier Ltd. All rights reserved.5 58 88 96; fax: þ47 55 58 98 77.
sykp.uib.no (M.J. Hynninen).
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CBT for anxiety and depression in COPD 987Introduction on change in symptoms of anxiety and depression. MeasuresPsychological disturbances such as anxiety and depression
affect a substantial number of patients with chronic
obstructive pulmonary disease (COPD). Studies have
demonstrated prevalence rates of 19e40% for depression
and 28e36% for anxiety.1,2 Anxiety and depression can
significantly increase physical disability, co-morbidity,
morbidity, and health-care utilization, and interfere with
compliance with medical treatment.3 Psychological distress
has also been shown to account for a significant amount of
variance in patients’ health status and sleep quality.4,5
Women with COPD seem to have higher levels of anxiety
and depression compared to men.1
The co-morbid psychological disturbances in COPD are
often undetected or not treated adequately.6 However, the
ACCP/AACVPR Pulmonary Rehabilitation Guidelines Panel
has pointed out that psychological distress is not neces-
sarily concomitant of lung disease and can and should be
treated.7 Although pharmacotherapy has been recom-
mended as a treatment strategy for anxiety and depression
in this patient group,8 significant obstacles implementing
such interventions have been reported.9 In a feasibility trial
of antidepressant therapy, Yohannes et al.9 found that 72%
of depressed patients refused the treatment and only 14%
of those who accepted completed the trial.
Cognitive behavioral therapy (CBT) is a well-known
approach for treating anxiety and depression, which has
demonstrated effectiveness also for older adults.10
A systematic review of CBT for COPD patients with mild to
moderate anxiety or depression identified three randomized
controlled trials (RCT) and one non-randomized controlled
trial.11 Two RCTs demonstrated significant reductions of
anxiety or depression.12,13 However, these studies examined
the effect of CBT in combination with exercise training and
education. None of the reviewed studies selected specifi-
cally patients with clinically significant co-morbid anxiety or
depression. The overall conclusion of the review was that
there is scant evidence of the effectiveness of CBT for COPD
patients. Further studies addressing the effectiveness of
CBT for anxiety and depression in COPD patients are being
called for.3
In a more recent and larger RCT, Kunik et al. targeted
COPD patients with at least moderate anxiety and/or
depression.12 CBT in group format significantly improved
anxiety and depression but was not superior to COPD
education in groups. Participants in this study were
veterans and mainly males (96.2%). In the current study, we
aimed to examine further the CBT group approach tested
previously in the study of Kunik et al.,14 with a sample with
more equal gender distribution. The prevalence and
morbidity of COPD in women is increasing, and women with
COPD also report more dyspnea and lower health-related
quality of life compared to men, regardless of lung func-
tion and burden of smoking.15 The high prevalence of
psychological co-morbidity in women may contribute to
both dyspnea and impaired health-related quality of life.
The objectives of the present study were: (1) to examine
the effect of CBT on clinically significant symptoms of
anxiety and depression compared with enhanced standard
care; (2) to investigate the eventual effects of sex and ageof sleep and health status were included as secondary
outcomes, as these factors seem to be affected by
psychological distress,16 and thus could be expected to
respond to an improvement in mental health symptoms.
Materials and methods
Patient recruitment
Participants for the RCT were recruited from an outpatient
pulmonary clinic at the Haukeland University Hospital,
Bergen, Norway, and by newspaper advertisement. An
initial telephone interview was conducted to ensure that
the patients fulfilled the basic study criteria. Those with
a diagnosed COPD and who answered positively to two out
of five anxiety and depression questions from the PRIME-MD
questionnaire17 were invited to a screening interview.
Eligibility criteria were (1) age 40 years or older; (2)
COPD diagnosis confirmed by post-bronchodilatory FEV1 of
less than 80% predicted and FEV1/FVC of less than 0.7; (3)
scores greater than 15 on the Beck Anxiety Inventory (BAI)
and/or greater than13 on the Beck Depression Inventory-II
(BDI-II)18,19; (4) not participating in other comprehensive
psychosocial interventions (i.e. pulmonary rehabilitation);
(5) no signs of cognitive impairment, defined by a score of
23 or higher on the Mini-Mental State Examination
(MMSE)20; and (6) no other severe psychiatric disorders as
identified by clinical assessment based on the Structured
Clinical Interview for the Diagnostic and Statistical Manual
of Mental Disorders, Fourth Edition (SCID I/P).21
We enrolled consecutive eligible patients interested in
participating in the study, for a period of 1.5 years. Of 328
patients interviewed in telephone, 186 fulfilled the basic
study criteria. Of those, 108 patients were not able or
willing to participate (problems with transportation nZ 30,
28%; does not feel anxiety/depression is a problem nZ 22,
20%; no time nZ 20, 17%; feeling too sick or fatigued
nZ 16, 15%; no data nZ 20, 19%), and 78 were invited to
screening interview. The study was approved by the
Regional Committee for Medical Research Ethics in Western
Norway and all patients gave informed consent.
Study design
Included patients were divided into matched pairs accord-
ing to their post-pronchodilatory FEV1 predicted, and from
each pair one participant was randomly assigned to CBT and
the other to enhanced standard care. Allocation conceal-
ment was implemented using numbered containers that
were identical in appearance for the two groups. Due to the
nature of the intervention, neither participants nor thera-
pists were blinded for group assignment. Patients in both
groups met at the pulmonary clinic for spirometry at
baseline and 2 and 8 months later. During these visits, they
also received the self-report measures and actigraph
devices for sleep registration, which they mailed to the
study personnel one week later. The primary outcome
measures for anxiety and depression were also adminis-
tered half way through the intervention period (week 4).
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CBT. Table 1 summarizes the components of the CBT
intervention. The CBT intervention was based on a man-
ualized group approach developed by Stanley et al.,22
tested previously by Kunik et al.14 The original therapy
manual was modified by cutting down the number of
components (from 7 to 6) and sessions (from 8 to 7) and
lengthening the session from 1 to 2 h, in order to allow for
more time to work on each component. The primary aim of
the intervention was to help patients modify beliefs and
change behavioral patterns that perpetuate or maintain
psychological and somatic symptoms.
The participants attended 7 weekly 2 h group sessions at
the university outpatient clinic (Department of clinical
psychology, University of Bergen, Norway). In each of the
treatment groups, there were 4e6 participants (5 on
average). Participants in the CBT intervention were phoned
one and three months after post-treatment assessment,
and encouraged to maintain behavioral changes instigated
by the therapy. The group sessions were facilitated by
a Masters-level psychology student. The sessions were
videotaped, and a specialist in clinical psychology moni-
tored the adherence and competence of the two student
therapists on the basis of the video recordings.
Control group. In addition to standard care for COPD,
participants in the control group received telephone
contact with the study personnel every two weeks in theTable 1 Key components of the CBT intervention.
Component Aim
Psychoeducation/
awareness
Increase awareness of how COPD m
psychological well-being, and how
psychological symptoms and behavio
patterns associated with anxiety an
depression may add to the burden o
lung disease.
Relaxation Use breathing techniques and postu
changes for relaxation and coping w
physical symptoms.
Cognitive therapy Identify and challenge depressive p
thought or anxiety-related ruminati
thoughts, and explore more functio
patterns of thought.
Behavioral activation Identify depressive, passive behavio
replace them with activities that ar
and/or increase one’s sense of mast
Fear-based exposure Replace avoidance of anxiety-provo
situations and activities with graded
exposure, in order to increase toler
reduce anxiety.
Sleep management skills Learn about sleep hygiene and use
management skills when needed.intervention period of seven weeks, in order to monitor
their psychological status and assess suicidal ideation. The
telephone calls lasted 5e10 min, and no interventions
beyond assessment of symptom level and basic informa-
tion about symptoms of anxiety and depression were
delivered. The telephone contact with the participants in
control group was facilitated by the student therapists
who also conducted the CBT treatment. There was no
monitoring of telephone contact, but the student thera-
pists received detailed written instructions for the tele-
phone calls.
Measures
The primary outcome measures were the BAI and the BDI-II.
Clinically significant anxiety was defined as a BAI score of 16
or higher (moderate to severe anxiety), since this repre-
sents a level of anxiety that is approximately two standard
deviations above the mean for an older community
sample.23 Clinically significant depression was defined as
a BDI-II score of 14 or higher (mild to severe depression).
This score corresponds to an empirically derived cut-off for
differentiating between community and clinical adult
samples.24
Secondary outcome measures were the St. George’s
Respiratory Questionnaire (SGRQ; perceived health
status),25 the Pittsburgh Sleep Quality Index (PSQI;
subjective sleep quality),26 and actigraphy (objectiveExample
ay affect
ral
d
f the
Explaining how dyspnea may set off panic
anxiety, and how anxious thoughts or
catastrophizing about physical symptoms
may contribute to Dyspnea.
ral
ith
Practicing relaxation with diaphragmatic
breathing when feeling ‘‘jittery’’.
atterns of
on/fearful
nal
Depressive thought pattern: Blaming self
for being ill and not being able to take
care of house and family.
More functional thought: ‘‘I am doing my
best under the circumstances and I can ask
for help when I need it.’’
rs and
e pleasant
ery.
Depressive pattern: sitting on the couch
and watching TV, while ruminating about
past failures.
Behavioral activation: making a plan to
go for a walk three times a week with a
neighbor.
king
ance and
Fear-based avoidance: restaurants,
movie theatres, shopping malls.
Exposure: going to a shopping mall with
a trusted friend for 15 min. Planning ahead
and practicing breathing techniques.
sleep Going to bed and getting up at the same time
every morning, restricting afternoon nap
to max. 15 min.
CBT for anxiety and depression in COPD 989sleep efficiency). On the SGRQ, higher scores imply more
impairment in perceived health status, and a four unit
change is considered to be clinically significant. On the
PSQI, a total score of greater than 5 has yielded a high
diagnostic sensitivity and specificity distinguishing poor
from good sleepers. Concerning actigraphic sleep
measurement, sleep efficiency below 85% is a common
cut-off value for making a diagnosis of insomnia in
adults.27
Spirometry was performed with a Vitalograph S-model
according to the ATS criteria.28 Demography, smoking
status, and medical co-morbidities were assessed from
participant self-report. The Client Satisfaction Question-
naire (CSQ) was used to assess participants’ satisfaction
with treatment.29 Scores range from 8 to 32, higher scores
indicating more satisfaction with the treatment.
Statistical analyses
Statistical analyses were performed with the SPSS statis-
tical software, version 14. Intention-to-treat analyses were
used. Mixed models with random effects were used to
examine the change on outcome variables over time and to
compare changes between groups from baseline to follow-
up.30 In contrast to the ANOVA approach, using mixed
models with random effects allows fitting a line for each
individual based on available data, and missing values at
one measurement point did not prevent including an indi-
vidual in the analysis.31 The models included terms for
time, quadratic time to account for nonlinear change,
group, and interaction of group with time/nonlinear time,
and the model with best fit with the data was chosen for
each outcome variable. In further pre-specified exploratory
analysis, terms for sex and age were added to examine the
contribution of these variables (main effect and three-way
interactions sex group time and age group time).
Assessment time (weeks from baseline) for posttest and
follow-up assessments were specified in the models for
each individual, in order to take into account possible78 Assessed for eligibility
51 Randomized
25 Assigned to Cognitive
Behavioral Therapy
23 Received allocated 
intervention
2 Discontinued intervention
26 
23 
23 Completed follow-up
assessments
18 C
a
2
2
1
25 Analyzed 26 A
Figure 1 Partideviations when participants were not available for the
pre-scheduled follow-up appointments. The flexibility of
the mixed models approach obviates the need for parallel
measurements, since the mean and variability structures
can be clearly separated.32
Secondary analysis using t-tests were conducted to
examine within-group time effect from pretreatment to
post-treatment and from post-treatment to follow-up.
Within-group effect sizes were expressed with the
Cohen’s d.33 Between-group effect sizes (d ) with 95%
confidence intervals were computed using the software
program DSTAT.34
Expecting a difference between the groups at follow-up
equivalent of an effect size of approximately 0.8, with
a power of 0.80 and an alpha at PZ 0.05, the number of
participants needed in each group was estimated to be 33.Results
Study population
The number of participants estimated in the power analysis
was not reached by the end of the study period. Fig. 1
shows the participant flow in the study. Seventy-eight
patients were assessed for eligibility and 22 were
excluded for not fulfilling the eligibility criteria. Five
withdrew from the study before randomization. Forty-six of
the 51 participants originally randomized completed the
intervention (23 women, 23 men).
Participant characteristics are summarized in Table 2.
Seventeen participants (33.3%) fulfilled the diagnostic
criteria (DSM-IV; based on clinical assessment with the SCID
I/P) for a mood disorder, 13 (25.5%) for an anxiety disorder,
and 23 (45.1%) for a mood disorder or anxiety disorder.
There were no statistically significant differences between
the groups in any of the clinical or sociodemographic vari-
ables, except for mean education years (CBT> Control
group, PZ 0.040).27 Excluded
18 Scores Below Cut-off on
BAI/BDI
5 Withdrew
2 Suicidal
2 Substance abuse
Assigned to Treatment-as-usual
Received allocated intervention
2 Could not be contacted
1 Died
ompleted follow-up
ssessments
 Withdrew
 Unavailable
 Died
nalyzed
cipant flow.
Table 2 Participant characteristics.
Characteristic CBT
(nZ 25)
Control group
(nZ 26)
Sex, women/men 11/14 15/11
Age, mean (SD, Range) 59.3
(7.6, 41e74)
62.6
(9.9, 41e78)
Mean education yrs.
(SD)
13.1 (3.8) 11.2 (2.1)
Mean FEV1 % predicted
(SD)
59.8 (21.1) 57.8 (25.8)
Current smokers, no.
(%)
6 (24) 7 (26.9)
Co-morbid illnesses,
mean (SD)
1.7 (1.1) 2.6 (1.9)
SCID diagnosis, no. (%) 10 (40) 13 (50)
CBT, cognitive behavioral therapy; FEV1, forced expiratory
volume in one second; SCID, Structured Clinical Interview for
the Diagnostic and Statistical Manual of Mental Disorders; SD,
standard deviation.
990 M.J. Hynninen et al.Primary and secondary outcomes
Mean values for all outcome measures at baseline, post-
treatment and follow-up are presented in Table 3.Table 3 Outcome data at all assessment points and effect size
Measure Time Cognitive behavioral therapy
(nZ 25)
Mean (SD) ES; Cohen’s
(95% CI)
Anxiety (BAI) Pretreatment 17.5 (7.3)
Post-treatment 12.7 (6.8)*** 0.7 (0.1e1.
Six-month
follow-up
11.0 (6.1)* 1.0 (0.4e1.
Depression(BDI-II) Pretreatment 20.7 (8.6)
Post-treatment 14.8 (7.8)*** 0.7 (0.1e1.
Six-month
follow-up
13.4 (5.9) 1.0 (0.4e1.
Health status
(SGRQ)
Pretreatment 54.8 (13.1)
Post-treatment 50.9 (11.5) 0.3 (0.2 t
Six-month
follow-up
51.6 (11.3) 0.3 (0.3 t
Sleep efficiency %
(actigraphy)
Pretreatment 86.0 (9.5)
Post-treatment 86.4 (7.4) 0 (0.5 t
Six-month
follow-up
89.3 (6.7)* 0.4 (0.2 t
Sleep quality
(PSQI)
Pretreatment 9.8 (4.4)
Post-treatment 9.5 (3.5) 0.1 (0.5 t
Six-month
follow-up
8.8 (3.6) 0.2 (0.3 t
ES, Effect size; SD, standard deviation; BAI, Beck Anxiety Inventory; B
Questionnaire; PSQI, Pittsburgh Sleep Quality Index.
*P< 0.05, ***P 0.001; P value is based on paired-samples t tests t
pretreatment to post-treatment and post-treatment to 6-month folloFig. 2 shows the change over time in the BAI and the
BDI-II scores in both groups, for women and men, as esti-
mated by the mixed models with random effects. Signifi-
cant group by time (FZ 23.18; d.f.Z 110, 365; P< 0.001)
and group by nonlinear time (FZ 16.40; d.f.Z 110, 204;
P< 0.001) interactions emerged for the BAI, implying that
the groups differed in the rate and manner of change. The
BAI scores in the CBT group were significantly improved
from baseline to post-treatment (PZ 0.001) and the
improvement continued during the follow-up period
(PZ 0.041). The change in the control group was not
significant. Female sex and younger age were associated
with higher BAI scores at baseline. However, there were no
differential interaction effects by sex or by age on the BAI
scores.
For the BDI-II, a significant group by time interaction
(FZ 5.78; d.f.Z 45, 559; PZ 0.020) was present. The
improvement from baseline to post-treatment was
significant in the CBT group (P< 0.001), whereas in the
control group there was no significant change. From post-
treatment to follow-up, there was some further
improvement in the CBT group but the change was not
significant. A negative covariance between intercepts and
slopes (rate of change) implied that individuals with lower
scores at baseline changed less compared to individuals
with higher baseline scores. Sex and age had significant
main effects for the BDI-II scores, female sex and younger
age being associated with more depressive symptoms ats with 95% confidence intervals.
Control group (nZ 26) Between-group ES,
Cohen’s d (95% CI)
d Mean (SD) ES; Cohen’s d
(95% CI)
17.5 (9.5)
2) 18.7 (10.0) 0.1 (0.7 to 0.4) 1.1 (0.5e1.7)
5) 18.7 (10.1) 0.1 (0.7 to 0.4) 1.4 (0.7e2.0)
20.5 (9.7)
3) 19.5 (9.4) 0.1 (0.4 to 0.6) 0.9 (0.3e1.5)
6) 19.7 (8.9) 0.1 (0.5 to 0.6) 0.9 (0.3e1.5)
59.2 (12.8)
o 0.9) 58.6 (13.6) 0 (0.5 to 0.6) 0.3 (0.2 to 0.9)
o 0.8) 60.6 (13.2) 0.1 (0.7 to 0.4) 0.4 (0.2 to 0.9)
89.0 (7.8)
o 0.6) 89.9 (8.2) 0.1 (0.4 to 0.7) 0.1 (0.5 to 0.6)
o 1.0) 88.0 (7.2) 0.1 (0.7 to 0.4) 0.5 (0.1 to 1.0)
8.4 (4.2)
o 0.6) 9.0 (4.5) 0.1 (0.7 to 0.4) 0.3 (0.3 to 0.8)
o 0.8) 8.6 (3.9) 0 (0.6 to 0.5) 0.3 (0.3 to 0.8)
DI-II, Beck Depression Inventory-II; SGRQ, St George’s Respiratory
o examine time effects within each treatment condition; from
w-up.
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Figure 2 Change in anxiety (BAI) and depressive symptoms (BDI-II) for men and women in both groups from baseline to follow-up,
as estimated by the mixed models.
CBT for anxiety and depression in COPD 991baseline. The three-way interaction age group time
was significant (FZ 19.65; d.f.Z 42, 735; P< 0.001),
which indicates that across the two groups, age had
a differential effect on change over time. In the control
group, younger patients tended to get worse over time
and there was a larger variance in outcomes between
younger and older patients in the control group compared
to the CBT group.
In the CBT group, there was a significant improvement in
sleep efficiency from post-treatment to follow-up
[t(22)Z2.65, PZ 0.015]. No significant interaction
effects were found for any of the secondary outcome
measures.
Satisfaction with treatment
The mean score was 28.8 (SD 2.4; range 25e32), implying
a high satisfaction with the CBT intervention.
Discussion
Our study investigated the effect of group CBT as a treat-
ment for anxiety and depression in a COPD outpatient
sample with a wide range of disease severity. In contrast to
previous randomized trials examining the effect of CBT, thestudy sample comprised patients with clinically significant
symptoms of anxiety and depression and had an equal gender
distribution. The significant findings of our study are that (1)
a CBT group intervention may provide relatively rapid
symptom relief for COPD patients with clinically significant
levels of anxiety and depression; (2) women have higher
levels of anxiety and depression, and although their symp-
toms may be improved with CBT, the symptom level remains
higher relative to men; (3) although younger age is associ-
ated with more anxiety and depressive symptoms, age does
not have an effect on responsiveness to CBT; (4) sleep and
health status do not seem to improve significantly as
a consequence of reduction in mental health symptoms.
The symptoms of anxiety and depression significantly
improved in the CBT group compared to the control group
(between-group ES 1.4 and 0.9, respectively), and most
change occurred during the 8-week period from baseline to
posttest assessments. The relatively rapid improvement is in
line with the results of Kunik et al.14 In the present study, the
CBT intervention included more hours than the previous
group trial, therefore allowing for somewhat more individ-
ualized attention, whichmay in turn have been beneficial for
achieving larger treatment effects. The participants repor-
ted also high levels of satisfaction with the intervention.
In the present study, women had higher levels of both
anxiety and depression at baseline, and their symptom
992 M.J. Hynninen et al.levels remained relatively high throughout the follow-up
period compared to men. Women seem to be more
susceptible to some of the systemic complications in COPD,
such as muscle dysfunction or fat-free body mass deple-
tion,35 of which depression may be a consequence.36
Women may also have a tendency to cope with the illness
in unfavorable ways, which might elevate emotional
distress.37 Special attention for women may be required, in
order to identify and treat mental health distress, and to
maintain the improvement.
Although psychological disturbance has sometimes been
linked to higher age or more severe COPD,38,39 younger
patients in our sample had higher levels of both anxiety and
depression than older patients. Also other studies have
found high prevalence of psychological distress even in
patients with mild COPD.1 In our study, age had also
differential effects in the two groups on change in
depressive symptoms over time, and in the control group
there was larger variance in outcomes between younger
and older patients. However, both younger and older
patients in the CBT group seemed to respond well to the
treatment, which suggests that CBT may be a suitable
treatment alternative for a wide age range of COPD
patients.
We also examined the potential of CBT for beneficial
effects on health status and sleep. Although sleep prob-
lems have been associated with anxiety and depression in
COPD,40 previous trials have not included measures of
sleep. In our study, objectively measured sleep efficiency
in the CBT group was within normal range at baseline but
showed some improvement at follow-up, whereas
patients’ own ratings indicated an unchanged experience
of poor sleep at all measurement times. Rather than
resulting from actual lack of sleep or insomnia, sleep
complaints in COPD patients may reflect feelings of
fatigue during the day as a consequence of the lung
disease, and possibly also poor sleep quality and breathing
disorders during sleep. Anxiety and depression can influ-
ence feelings of fatigue, but improvement in psychological
symptoms may not be sufficient in itself to reduce sleep
complaints significantly.
Limitations
Our study had certain limitations. Although there were
statistically significant differences between the groups in
change in anxiety and depression, as a consequence of the
low sample size it is possible that other significant differ-
ences were not detected when they truly existed. With
a larger sample size, age might have had an effect also on
change in anxiety symptoms. The differences between the
groups on sleep and health status were also not statistically
significant. However, both sleep problems and health status
are likely to be connected to the underlying respiratory
illness, and thus may not respond to improvement in
emotional symptoms.
Since many of the patients who were initially contacted
declined to participate, the generalizability of the results
may be limited. For those who responded positively to the
PRIME-MD questions for anxiety and depression in the initial
telephone interview but did not wish to participate (58%,
108 out of 186 patients), the most common reported reasonwas problems with transportation, followed by not
believing that depressed or anxious feelings were
a problem, being too busy, or feeling too sick or fatigued to
participate. In the framework of the present trial, it was
not possible to address the problems with transportation or
provide more individualized attention. Thus, it is possible
that the participants in this study may represent a patient
population that is in relatively good health, has more
resources available and/or is well suited for psychosocial
interventions or group treatment. However, some propor-
tion of the patients who declined to participate may also
not have suffered from anxiety or depression to a signifi-
cant degree and this may have reduced their motivation to
participate.
Clinical implications and future research
Our results alongside with previous findings41 underline the
need for a comprehensive treatment approach that
addresses the complex web of medical illness, disability
and psychological distress, by integrating mental health
care into the overall medical regimen. The benefits of
existing treatment alternatives, such as multidisciplinary
pulmonary rehabilitation (PR), may be improved by tar-
geting also more explicit psychological health aspects.
Components of CBT may be integrated into PR programs
relatively easily and be helpful for many patients, regard-
less of their psychological status. For example, psycho-
education and increased awareness of the role of
psychological symptoms in COPD are likely to be useful
knowledge for all patients. Breathing retraining is
a common component in PR programs, and patients can
benefit from learning how to use breathing techniques and
exercises to relax and manage anxiety. Similarly, exercise
and behavioral activation are often part of PR, and their
role in improving psychological health and reducing
anxiety-related avoidance and depressive patterns can be
emphasized. The potential benefits of integrating mental
health care in existing treatment alternatives, such as PR,
should be addressed in future studies. Also, more studies
focusing on the impact of sleep and its connections to COPD
and psychological symptoms are needed.
For patients with more severe disability and/or psycho-
logical distress, CBT in group format may not be appro-
priate, and there seems to be a need for a more
individualized approach to overcome the barriers for care.
Due to a shortage of CBT practitioners and resources,
individual treatment may be difficult to provide, and
computerized and telephone-delivered CBT have been
suggested as alternatives.42 Problem-solving skills-training
to address behavioral limitations as well as access to a care
manager who works with the patient to identify and
overcome the specific barriers have been suggested as ways
to improve adherence to treatment.41,43 Future studies
should compare individually delivered CBT to group CBT, as
well as examing the effectiveness of group CBT delivered
by non-mental health professionals, such as nurses or other
health personnel.
For future trials of CBT for COPD patients, there is also
a need to address how best to provide support and assur-
ance to potential participants, in order to facilitate the
participation and ensure an adequate participation rate.
CBT for anxiety and depression in COPD 993Strategies such as arranging transportation, flexibility and
attention to and flexibility in terms of assessment and
treatment locations and times (e.g. availability of public
transportation and parking, running groups during the day
and after work hours), and assurance regarding fears or
concerns about participation may be employed.
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